BCM
MLTX icon

Boxer Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Boxer Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.13M Hold
275,000
– – 0.67% 34
2025
Q4 		$3.62M Buy
275,000
+25,000
+10% +$295K 0.79% 33
2025
Q3 		$1.79M Buy
+250,000
New +$13M 0.57% 25

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Boxer Capital Management's MLTX Position: Q1 2026 in Review

Boxer Capital Management held its MoonLake Immunotherapeutics (MLTX) position steady in Q1 2026 at 275,000 shares worth $5.13M. The position accounts for 0.67% of the portfolio, ranked #34.

Boxer Capital Management first reported a position in MLTX in Q3 2025 and has held it in 3 quarters since. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • Boxer Capital Management held 275,000 shares of MoonLake Immunotherapeutics worth $5.13M as of Q1 2026.
  • Boxer Capital Management left its MoonLake Immunotherapeutics share count unchanged in Q1 2026.
  • MoonLake Immunotherapeutics made up 0.67% of Boxer Capital Management's portfolio in Q1 2026, its #34 holding.
  • Boxer Capital Management first reported a position in MoonLake Immunotherapeutics in Q3 2025 and has held it in 3 quarters since.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Boxer Capital Management's 13F filing for Q1 2026, filed 15 May 2026.